![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-Containing Regimens in HIV-Infected 4 Weeks to <2-Year-Old Children 48-Week Data From Study APV20002
|
|
|
Reported by Jules Levin
19th International AIDS Conference
July 22-27, 2012; Washington, DC
M Cotton, H Cassim, N Pavia-Ruz, L Ross, S Ford, N Givens, K Cheng, J Sievers
![IAC1.gif](../images/073112/073112-4/IAC1.gif)
![IAC2.gif](../images/073112/073112-4/IAC2.gif)
![IAC3.gif](../images/073112/073112-4/IAC3.gif)
![IAC4.gif](../images/073112/073112-4/IAC4.gif)
![IAC5.gif](../images/073112/073112-4/IAC5.gif)
![IAC6.gif](../images/073112/073112-4/IAC6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|